From the Journals

Common parasite now tied to impaired cognitive function


 

Prevention programs warranted

Commenting on the study in an interview, Shawn D. Gale, PhD, associate professor, department of psychology and neuroscience center, Brigham Young University, Provo, Utah, called it a “great meta-analysis.” He noted that his group is researching the subject and has obtained similar findings. A big plus is that the researchers assessed several cognitive domains, not just one.

Although the data showed “mild effects,” the findings could be important on a population level. Because 30% of the world’s population are seropositive for T. gondii, a potentially large number of people are at risk for cognitive impairment, noted Dr. Gale, who was not involved with the study.

“If you look at the United States, perhaps 10%-15% of people might test positive [for T. gondii], but in Germany and France, the number comes closer to 50%, and in other places in the world – especially countries that have a harder time economically – the rates are even higher. So if it can affect cognition, even a small effect is a big deal,” Dr. Gale said.

“I think prevention will be the most important thing, and perhaps down the road, I hope that a vaccine will be considered,” Dr. Gale added.

“These findings indicate that primary prevention of the infection could have substantial global impact on mental health” and that public health programs to prevent T. gondii “are warranted.”

These programs might consist of hygienic measures, especially after human contact with contaminated sources, as well as research into vaccine development.

No source of funding for the study was listed. The authors and Dr. Gale reported no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Memory benefit seen with antihypertensives crossing blood-brain barrier
MDedge Neurology
No overall statin effect seen on dementia, cognition in ASPREE analysis
MDedge Neurology
FDA leader explains rationale leading to controversial Alzheimer’s drug approval
MDedge Neurology
FDA fast-tracks lecanemab for Alzheimer’s disease
MDedge Neurology
Hearing loss tied to decline in physical functioning
MDedge Neurology
Chronic stress and genetics can raise the risk of Alzheimer’s disease
MDedge Neurology
FDA updates label for controversial Alzheimer’s drug aducanumab (Aduhelm)
MDedge Neurology
FDA head calls for investigation into agency’s approval of aducanumab (Aduhelm)
MDedge Neurology
Contentious Alzheimer’s drug likely to get national coverage plan, CMS says
MDedge Neurology
Zero benefit of aducanumab for Alzheimer’s disease, expert panel rules
MDedge Neurology